The company is said to be developing NurOwn to treat ALS which is a progressive neurodegenerative disease, Reuters reported.
The researchers transplanted the patients with their own stem cells from the bone marrow which were then subjected to NurOwn stem cell technology treatment.
The first phase of the study is intended to assess the safety of the drug candidate while the efficacy will be evaluated at a later stage.